海辰药业(300584) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥111,634,892.16, a decrease of 18.29% compared to the same period last year[5]. - Total operating revenue for Q3 2022 was ¥379,213,500.69, a decrease of 16.4% compared to ¥453,522,480.87 in Q3 2021[20]. - Operating profit for Q3 2022 was ¥23,657,656.42, a decline of 21% from ¥29,936,871.36 in Q3 2021[20]. - Net profit attributable to shareholders was ¥2,360,978.20, down 66.73% year-on-year[5]. - Net profit for the third quarter was ¥19.76 million, down 28.5% from ¥27.53 million year-over-year[21]. - Basic and diluted earnings per share were both ¥0.1674, compared to ¥0.2353 in the previous year, reflecting a decline of 29%[21]. Cash Flow - The company reported a net cash flow from operating activities of -¥53,606,799.17, a significant decline of 268.17%[5]. - Cash flow from operating activities showed a net outflow of approximately ¥53.61 million, contrasting with a net inflow of ¥31.88 million in the same quarter last year[22]. - The net cash flow from investment activities increased by 242.95% to ¥101,958,136.28, driven by equity transfer gains and investments in financial products[10]. - Cash inflow from investment activities was approximately ¥457.39 million, significantly higher than ¥40.15 million in the previous year[22]. - Cash flow from financing activities resulted in a net outflow of approximately ¥72.01 million, compared to a net inflow of ¥27.60 million in the previous year[23]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,236,939,727.03, a decrease of 5.00% from the end of the previous year[5]. - Total current assets reached ¥368,903,155.77, up 22.1% from ¥301,955,213.06[18]. - Total liabilities decreased to ¥298,363,396.37 from ¥353,530,387.82, a reduction of 15.6%[18]. - Non-current assets totaled ¥868,036,571.26, down 13.2% from ¥1,000,053,089.99[18]. Accounts and Inventory - Accounts receivable increased by 38.48% to ¥153,636,321.57 due to slower customer payment collection[9]. - Inventory rose to ¥65,911,272.79, an increase of 19.5% compared to ¥55,160,644.73[18]. - Prepayments rose by 147.55% to ¥16,680,139.96 as a result of unsettled prepayments[9]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 15,890, with the largest shareholder holding 42.08% of the shares[12]. - The total number of restricted shares at the beginning of the period was 55,954,749, with an increase of 6,024,456 restricted shares by the end of the period[14]. Other Financial Metrics - The basic earnings per share decreased by 66.67% to ¥0.0197[5]. - The weighted average return on equity was 0.25%, down 0.78% from the previous year[5]. - The company reported a total non-operating income of ¥30,782.10 for the reporting period[6]. - The company's minority shareholder equity dropped by 100% to ¥0, as a subsidiary's minority shareholders exited, converting their equity to capital reserves[10]. - The company reported a 129.39% increase in asset impairment losses to -¥2,316,534.59, due to increased provisions for inventory depreciation[10]. Market Conditions - Sales expenses fell by 30.14% to ¥186,390,916.67, primarily due to market promotion restrictions caused by the pandemic[10]. - Cash received from sales of goods and services totaled ¥359.67 million, down 25% from ¥478.99 million year-over-year[22]. Audit Status - The company has not undergone an audit for the third quarter report[24].